Cost-utility analysis of certolizumab pegol versus...

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Hidalgo-Vega, Álvaro, Villoro, Renata, Blasco, Juan Antonio, Talavera, Pablo, Ferro, Belén, Purcaru, Oana
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
13
Language:
english
Journal:
Cost Effectiveness and Resource Allocation
DOI:
10.1186/s12962-015-0037-9
Date:
December, 2015
File:
PDF, 1.61 MB
english, 2015
Conversion to is in progress
Conversion to is failed